Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics develops personalized immune therapies for cancer using the DCVax platform technology. Lead product DCVax-L treats Glioblastoma multiforme brain cancer after completing Phase III clinical trials. Another product, DCVax-Direct, is in Phase I/II trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

0.2 USD

Potential

-100%

Strengths

The company has high returns. ROIC (100.00%) is higher than the sector mean (6.02%).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
EBITDA Margin (0.00%) appears relatively low.

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	100.0%
Net Debt/EBITDA	100.0

Northwest Biotherapeutics, Inc.

Overview

Strengths

Weaknesses

Key Financial Data